Purified malignant mammary epithelial cells maintain hormone responsiveness in culture

MS Kothari1, S Ali1, L Buluwela1, N Livni2, S Shousha2, HD Sinnett3, R Vashisht4, P Thorpe5, S Van Noorden6, RC Coombes1 and MJ Slade*1

1Department of Cancer Cell Biology, Imperial College, Du Cane Road, London W12 ONN, UK; 2Department of Histopathology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK; 3Department of Surgery, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK; 4Department of Surgery, West Middlesex University Hospital, London TW7 6AF, UK; 5Department of Histopathology, West Middlesex University Hospital, London TW7 6AF, UK; 6Department of Histopathology, Imperial College, Du Cane Road, London W12 ONN, UK

Currently, the therapy for breast cancer is determined by immunohistochemical staining of the primary tumour for oestrogen receptor alpha (ERα). However, a proportion of ERα-positive patients fail to respond to tamoxifen and a proportion of ERα-negative patients show response. Here, we describe a novel procedure for the purification of malignant breast epithelial cells in an attempt to identify these patients at an early stage. Using this procedure, we are able to purify malignant cells to >90% purity as determined by immunohistochemical staining, cytology and fluorescent in situ hybridisation (FISH). While the malignant cells can be maintained in culture they do not proliferate in contrast to purified breast epithelial cells from reduction mammoplasties. Moreover, ERα and progesterone receptor (PR) expression is maintained in malignant cells, whereas normal epithelial cells rapidly lose ERα and PR. Functional studies were performed on the separated malignant cells in terms of their response to oestriadiol and tamoxifen. Four out of the seven ERα-positive tumours showed a significant reduction in cell numbers after tamoxifen treatment compared to oestriadiol, ERα-negative tumours failed to show a response. We conclude that (a) it is possible to purify and maintain breast cancer cells for a sufficient period to permit functional studies and (b) ERα is retained in culture facilitating the use of these cells in studies of the mechanism of endocrine response and resistance in vitro.

British Journal of Cancer (2003) 88, 1071 – 1076. doi:10.1038/sj.bjc.6600866 www.bjcancer.com © 2003 Cancer Research UK

Keywords: primary cells; oestrogen receptor; hormone responsiveness

The human mammary gland is comprised of two epithelial cell components, namely luminal epithelial and myoepithelial cells, both of which can be purified by immunoaffinity techniques that exploit differences in cell surface protein expression (Clarke et al, 1994; Gomm et al, 1995, 1997a; Kamalati et al, 1999; Niranjana et al, 1995; Page et al, 1999; Slade et al, 1999). Using such protocols, it has been possible to further study and highlight the responses of these two cell types to growth and morphogenic signals, thereby gaining further insight into the functionality of these cells in normal mammary gland function.

It is thought that luminal epithelial cells are the main precursor cell population from which breast cancers arise, although gene expression studies indicate that there may be myoepithelial gene expression signature in a significant number of such tumours (Perou et al, 1999, 2000). Nevertheless, comparison of tumour and normal cells highlight oestrogen receptor alpha (ERα) expression in breast cancer, a protein found to be expressed in approximately 20% of all cells in the normal mammary gland (Russo et al, 1999), and 87% of ER-positive cells are luminal epithelial cells or in an intermediate position in the duct wall (Petersen et al, 1987). ERα is expressed in 50–70% of all breast cancers, where endocrine therapy directed at inhibiting ERα function is used as a treatment following surgery. From this, and through observations in animal models it is clear that oestrogen is an important growth and/or survival factor in breast cancer. However, the response of primary human breast tumour cells to oestriadiol and antioestrogens remains poorly studied. Although there are a number of ERα-positive breast cancer cell lines, these may not be the best vehicle for studying in vivo response. These problems have prompted us to evaluate the potential for immunoaffinity purification to characterise primary human breast tumour cells. In doing this, we sought to modify our original protocols for the purification of normal mammary epithelial cells so that they can be applied to both the normal and malignant mammary gland. By exploiting the expression of epithelial cell adhesion molecule (Ep-CAM) antigen, found on the surface of primary luminal epithelial and tumour cells, we have been able to obtain near homogeneity in purifications for both cell types. Surprisingly, we find that even though both tumour and normal cells are purified using similar protocols, ERα expression in primary normal cells is unstable and is rapidly attenuated. By contrast, ERα expression is stable and can be maintained in cultures of purified malignant epithelial cells. Finally we show that, under conditions that stimulate growth of the normal cells purified, tumour cells do not proliferate and remain in this quiescent state, even following treatment with oestrogen.
MATERIALS AND METHODS

Tissues used

Fresh tissue was obtained from 82 cases of primary breast carcinoma (Table 1) and six cases of reduction mammoplasty, which on subsequent histopathological examination showed no signs of malignancy or other abnormality. Of the 82 primary breast carcinomas (Table 1), 31 were used for development of the purification protocol/culture conditions and 19 resulted in insufficient cells for any studies. Of the remaining 32 samples, 18 were examined cytologically and of these five were also analysed by fluorescent in situ hybridisation (FISH) and seven were stained for ERx/PR. Four samples were used in thymidine incorporation, seven in the oestrogen/tamoxifen studies and the remaining three were used for adherence studies. All patients were treated at Charing Cross and West Middlesex Hospitals, London, and gave written, informed consent as required by the local Ethics Review Board.

Purification of normal human mammary luminal epithelial cells

Cells were purified from breast tissue from reduction mammoplasties using a modification of procedures described previously (Gomm et al., 1995; Slade et al., 1999). Briefly, breast tissue was minced and digested overnight at 37°C with type IA collagenase (1 mg ml⁻¹) in RPMI-1640 plus 5% foetal calf serum (FCS) and 2 mM l-glutamine, 100 U ml⁻¹ penicillin, 0.1 mg ml⁻¹ streptomycin, 50 U ml⁻¹ polymyxin B, 2.5 mg ml⁻¹ amphotericin B. Following digestion, the fat was decanted off and the remaining organoids and cells were washed three times in media. Organoids were left to settle out for 20 min, the supernatants were removed, and cells were washed three times in media. Under these digestion conditions, the majority of normal epithelial cells remained in intact organoids or as clumps and were removed by the filtration steps. The tumour cells were purified as described above and isolated cells were cultured in BCM with 5% FCS (FCS concentrations from 1 to 10% were investigated and 5% resulted in the highest cell viability after 5 days in culture (data not shown)).

Characterisation of isolated tumour cells

Purified tumour cells were cytospun and stained with haematoxylin/eosin (H&E) and May Grunwald Giemsa (MGG). The percentage of malignant cells was determined by conventional cytology before purification, after purification and after 7 days in culture following purification.

ERx and progesterone receptor (PR) expression was assessed at different time points by immunostaining on cells fixed in Zamboni reagent (Stefanini et al., 1967), using anti-ERx (MAB NC-ER-6F11 Novocastra, Newcastle, UK) and anti-PR (MABPR-88, Menarini Diagnostics, Wokingham, UK) according to manufacturers’ protocols. Cell purity was determined by staining for cytokeratins 8 and 18 (MAB CAM 5.2, Becton Dickinson, Oxford, UK).

Fluorescent in situ hybridisation (FISH) analysis of purified cells was performed as described (Kallioniemi et al., 1992), using centromere-specific fluorescent probes (Vysis Inc., Downers Grove, IL, USA) for chromosomes 6, 7 and 12 (spectrum orange), 11, 17 and 18 (spectrum green) (Cajulis and Frias-Hidvegi, 1993; Persons et al., 1996). These were used to detect aneusomy according to the manufacturer’s instructions. Only cells exhibiting three or more spots were deemed to be showing aneusomy.

In order to assess the viability/adherence characteristics of the purified normal and malignant cells, 1 × 10⁵ cells were plated into 96-well plates. Three days postseeding, the medium was removed, the adherent cells were washed twice with PBS and the washings pooled with the medium. The number of viable and nonviable cells were counted using trypan blue. The adherent cells were removed by trypsinisation and counted. This process was repeated after 3 and 6 days. Purified cells from three reduction mammoplasties and three primary tumours were assessed.

Effects of oestradiol and tamoxifen

1 × 10⁵ cells were plated into 96-well plates. Culture medium was changed on the third day for BCM+5% FCS containing 17β-oestradiol (E2; 10 nM) or 4-hydroxytamoxifen (4 OHT; 100 nM) or an equal volume of the vehicle, ethanol. Total and viable (trypan blue) cell counts were measured during the time course of the experiment.

Table 1 Patient characteristics (n=82)

| Number | Percentage |
|--------|------------|
| Pathological size (cm) | |
| <2 | 32 | 39 |
| >2 | 50 | 61 |
| ER+/PR+ | 57 | 69 |
| ER+/PR− | 8 | 10 |
| ER−/PR+ | 3 | 4 |
| ER−/PR− | 14 | 17 |
| Histology | |
| Invasive ductal | 61 | 74 |
| Other/mixed invasive | 21 | 26 |
| Nodal status | |
| Positive | 42 | 51 |
| Negative | 40 | 49 |
| Grades | |
| III | 28 | 34 |
| II | 45 | 55 |
| I | 9 | 11 |

This shows the total number of patients from whom tumours were obtained during the study.
RESULTS

Optimisation of purification procedure

We have previously described procedures for the purification and culturing of normal human mammary luminal epithelial cells. In order to adapt these techniques to the purification and culturing of tumour cells, we have evaluated the use of Ber-Ep4 in this context. In doing this, we have exploited the differential collagenase treatment of normal mammary organoids compared to primary tumour cell aggregates, which show a markedly greater sensitivity to this process (this step is responsible for eliminating residual normal cell within the preparation). We have been able to show that careful use of collagenase leads to single-cell suspensions of tumour cells with normal cells remaining in aggregates large enough to be removed by conventional filtration. Prior to incubation with the immunolabelled beads, the median cell number was $1.5 \times 10^6$ (range: $1 \times 10^5$–$7 \times 10^6$). After purification, the median cell number was $3 \times 10^5$ (range: $0.3 \times 10^5$–$6 \times 10^5$). We also evaluated other parameters, including the ratio of beads to cells required to obtain tumour cell preparations of high purity. The number of beads: cell ratio was maximally $10:1$ when there were $<10^5$ cells but apart from this the optimised ratio was $3:1$, which we found to result in a high degree of purity without the cells being completely coated with beads.

| Table 2A Percentage malignancy as determined by cytology before and after (day 0) immunobead selection and after 7 days in culture |
|---|
| Pre-beads | Day 0 | Day 7 |
| T1 | 69 | 97 | 95 |
| T2 | 65 | 97 | 96 |
| T3 | 72 | 97 | 96 |
| T4 | 88 | 98 | 95 |
| T5 | 61 | 97 | 99 |
| T6 | 87 | 100 | 97 |

Characterisation of isolated tumour cells

Following collagenase digestion, the cells were assessed by cytology (Table 2A) and immunostaining for cytokeratins 8 and 18 expression (Figure 1A, C). After immunobead purification, the cells were assessed for purity and $>95\%$ of the purified cells showed abnormal cytology, and cytokeratin staining revealed that between 95 and 100\% (mean 97\%) of cells were positively stained (Figure 1B, D). There appeared to be only 1–5\% contamination (mean = 2\%), mainly because of the presence of degenerate cells and occasional macrophages. (Table 2B displays aneusomy using paired chromosome probes).

Immunostaining on a subset of ERa- and PR-positive tumours over 9 days showed that these phenotypes were retained throughout the time course studied in vitro (Table 3 and Figure 2A–D). However, in six normal cultures studied, there was a substantial reduction in expression of ERa and PR (Table 3 and Figure 2E–H). When this was examined in more detail, we observed that in fact there was a substantial reduction in ERa and PR expression within 24 h and ERa expression was not observed beyond this period whereas PR expression was lost in four cultures by 60 h (Figure 2I, J). Although this pattern of staining is not indicative of malignancy it does indicate that the epithelial cells isolated from the primary tumour were abnormal.

Figure 1 (A) H&E staining of cells from a primary tumour before purification, (B) H&E staining of cells from a primary tumour after purification, (C) cytokeratin 8 and 18 staining of cells from a primary tumour before purification, (D) cytokeratin 8 and 18 staining of cells from a primary tumour after purification (Bar represents 20 μm).
We studied the effects of oestradiol (E2) and 4OHT in ERa-positive and -negative tumours. As a result of a limited number of cells, studies were limited to two time points. Trypan blue staining determined viable cell numbers. The medium was changed on the third day of culture to E2 and 4OHT-containing medium, thereby allowing sufficient time for the cells to adhere to plastic.

Four (all ERa positive) of the seven tumours studied showed significant reduction in cell numbers after tamoxifen treatment compared to oestradiol treatment. The ERa-negative tumour failed to show a response (Figure 4A). The P-values were calculated for each tumour comparing ethanol control to oestriadiol, ethanol control to tamoxifen and oestradiol control to tamoxifen, and are shown in Figure 4B. We have shown that oestrogen is required for cell survival as primary tumour cells cultured in phenol red-free media +5% double-stripped serum had a markedly reduced cell viability within 24 h (data not shown). Therefore, residual oestrogen content of the FCS does not explain the lack of proliferation.

### DISCUSSION

We show, in this report, that enzymatic treatment of breast cancer, followed by immunomagnetic breast cell purification, yields extremely pure populations of breast cancer cells, as judged by cytology and FISH. These methods have been developed as a direct extension of our studies of normal breast cell purification (Gomm et al, 1995, 1997a; Slade et al, 1999) and demonstrate the value of immunomagnetic breast purification for both normal and neoplastic breast cells. Other results presented here demonstrate distinct differences in retention of ERa expression in normal and cancer cells with normal cells losing ERa expression within hours of purification. However, despite loss of ERa immunostaining in normal cells, we have evidence of retained ERa expression since the normal cells respond to oestrogen exposure by expressing both PR and PS2 (Zhuang et al, 2003), both of which are known to be oestrogen-regulated.

### Effects of oestradiol and tamoxifen

In order to confirm that the cells isolated from the primary tumour maintained an abnormal genotype in culture, we carried out FISH on a subset (n = 5) using probes for six chromosomes and compared this with normal cells purified from reduction mammoplasty specimens (n = 5). We compared the percentage showing aneusomy using paired chromosome probes before and after 7 days’ culture (Table 2B). It can be seen that between 85 and 92% of cells showed aneusomy at day 0 and 82–91% at day 7. The figure for individual probes was 26–88%. No normal breast epithelial cells showed aneusomy.

We examined the proportion of cells that retained viability and adherence in a subset of samples (n = 3). Figure 3 shows that, at day 3, more than 50% of cancer cells were viable and adhered to plastic. At day 9, this fell to approximately 40%. In contrast, the normal epithelial cells increased in number, so that the numbers at day 9 were greater than the number initially seeded. There was no evidence of proliferation of the cancer cells, despite the fact that the MTS assay (Promega Inc., Southampton, UK) indicated maintained cell viability (data not shown). In addition, thymidine-uptake measurements showed no uptake over 16 days (data not shown).

The number of viable cells is expressed as x 10^5. ERa and PR staining are expressed as a percentage. ND=not done.

### Table 3 ERa and PR staining of separated cells from seven primary tumours

| Tumour (ERa/PR status) | Viable cells | ERa | PR | Viable cells | ERa | PR | Viable cells | ERa | PR | Viable cells | ERa | PR | Viable cells | ERa | PR |
|------------------------|--------------|-----|----|--------------|-----|----|--------------|-----|----|--------------|-----|----|--------------|-----|----|
| T1 (+++/+)             | 0.7          | 35.0 | ND | 0.4          | 39.6 | ND | 0.4          | 39.6 | ND | 0.4          | 39.6 | ND | 0.4          | 39.6 | ND |
| T2 (+++/+)             | 2.0          | 44.0 | ND | 1.5          | 27.3 | ND | 1.5          | 27.3 | ND | 1.5          | 27.3 | ND | 1.5          | 27.3 | ND |
| T3 (+++/++)            | 0.9          | 28.4 | ND | 0.7          | 25.1 | ND | 0.7          | 25.1 | ND | 0.7          | 25.1 | ND | 0.7          | 25.1 | ND |
| T4 (+++/++)            | 4.1          | 65.0 | ND | 3.1          | 56.8 | ND | 3.1          | 56.8 | ND | 3.1          | 56.8 | ND | 3.1          | 56.8 | ND |
| T5 (+++/++)            | 6.0          | 25.3 | 64.4 | 4.5          | 30.9 | 64.4 | 4.5          | 30.9 | 64.4 | 4.5          | 30.9 | 64.4 | 4.5          | 30.9 | 64.4 |
| T6 (+++/++)            | 26.6         | 79.5 | 81.5 | 21.6         | 80.2 | 81.5 | 21.6         | 80.2 | 81.5 | 21.6         | 80.2 | 81.5 | 21.6         | 80.2 | 81.5 |
| T7 (+++/+)             | 3.2          | 5.8  | 3   | 2.9          | 5.2  | <3 | 2.9          | 5.2  | <3 | 2.9          | 5.2  | <3 | 2.9          | 5.2  | <3 |
| T8 (+/-)               | 0.2          | 32.9 | ND | 0.2          | 32.9 | ND | 0.2          | 32.9 | ND | 0.2          | 32.9 | ND | 0.2          | 32.9 | ND |
| T9 (-/-)               | 1.1          | 24.1 | ND | 1.1          | 24.1 | ND | 1.1          | 24.1 | ND | 1.1          | 24.1 | ND | 1.1          | 24.1 | ND |
| T10 (+/-)              | 0.5          | 24.4 | ND | 0.5          | 24.4 | ND | 0.5          | 24.4 | ND | 0.5          | 24.4 | ND | 0.5          | 24.4 | ND |
| T11 (+/-)              | 2.4          | 67.7 | ND | 2.4          | 67.7 | ND | 2.4          | 67.7 | ND | 2.4          | 67.7 | ND | 2.4          | 67.7 | ND |
| T12 (+/-)              | 2.7          | 28.8 | 53.6 | 2.7          | 28.8 | 53.6 | 2.7          | 28.8 | 53.6 | 2.7          | 28.8 | 53.6 | 2.7          | 28.8 | 53.6 |
| T13 (+/-)              | 1.35         | 60.1 | 64.0 | 1.35         | 60.1 | 64.0 | 1.35         | 60.1 | 64.0 | 1.35         | 60.1 | 64.0 | 1.35         | 60.1 | 64.0 |

The number of viable cells is expressed as x 10^5. ERa and PR staining are expressed as a percentage. ND=not done.
With regard to the observation that ERα expression is rapidly attenuated in normal cells, several mechanisms may be relevant. Firstly, growth factor signalling is known to regulate ERα expression through unclear mechanisms; the transcription factor AP2α is known to be important in regulating ERα expression and the levels of AP2α are elevated in breast cancer as compared to normal breast (Turner et al, 1998). Recent studies (Wijayaratne and McDonnell, 2001) have suggested a link between transcription factor AP2α levels and ERα expression.

![Figure 2](image-url) Figure 2 (A) ERα staining of cells from a primary tumour after immunobead purification (day 0), (B) ERα staining of cells from a primary tumour (day 7), (C) PR staining of cells from a primary tumour after immunobead purification (day 0), (D) PR staining of cells from a primary tumour (day 7), (E) ERα staining of cells from a reduction mammoplasty after immunobead purification (day 0), (F) ERα staining of cells from a reduction mammoplasty (day 7), (G) PR staining of cells from a reduction mammoplasty after immunobead purification (day 0), (H) PR staining of cells from a reduction mammoplasty (day 7). The bar on each figure represents 20 μm. (I) ERα and PR status of primary malignant mammary epithelial cells over 9 days expressed as the percentage change. There was a reduction in the percentage of cells positive for both ERα and PR; however, the majority of the malignant cells remained ERα- and PR-positive after 9 days in culture. (J) ERα (n = 6), (K) PR (n = 3), and (L) ERα and PR status of primary normal mammary epithelial cells over 96 h. Both receptors were rapidly lost in the normal cultures, so that after 36 h in culture, all the cells were ERα and PR negative. (M) ERα and (N) PR.

Hormone responsiveness by mammary cells

![Figure 3](image-url) Figure 3 Graph showing the viability of primary normal and malignant mammary epithelial cells over 9 days as determined by trypan blue staining and cell counting. The experiment started 3 days after the cells were seeded in order to allow for cell adherence. The adherent normal epithelial cells proliferate and hence the increase in numbers after the initial reduction between days 0 and 3. Approximately 60% of the malignant epithelial cells were adherent after 3 days and this fell to approximately 45% 9 days after seeding (∆). The number of floating dead malignant cells (□) and the floating live malignant cells (●) was low throughout the experiment.

![Figure 4](image-url) Figure 4 (A) The effects of oestradiol and tamoxifen in terms of cell survival on malignant mammary epithelial cells. (■) Oestradiol, (○) Tamoxifen. (B) Table showing the P-values for each tumour comparing ethanol control to oestradiol, ethanol control to tamoxifen and estradiol control to tamoxifen. An asterisk indicates a statistically significant difference.
factor activity and the rate of degradation, with greater activity equating with deceased protein stability. ERα is degraded via the 26S proteasome pathway and ubiquitination is influenced by ligands, unliganded receptor having a short half-life. It is hence possible that breast cancer cells, by virtue of their elevated aromatase content, have a higher likelihood of possessing ligand-occupied ERα (Wijayaratne and McDonnell, 2001).

Some groups have published protocols for the purification of breast cancer cells. Most remarkable of these have been Spiers et al. (1998), who used differential centrifugation to purify different cell types and Dairkee et al. (1997), who used partial enzymatic degradation. However, the methods used cannot exclude contamination from other cell types, particularly normal epithelial cells and fibroblasts. In Spiers’ method, overgrowth by normal epithelial cells is suggested by the observation that ERα expression was gradually lost over time (Spiers et al., 1998), whereas in Dairkee’s (1997) method, contamination by fibroblasts required differential trypsinisation. Unlike other groups (Dairkee et al., 1997), we have never observed proliferation of the purified neoplastic cells, in contrast to the normal luminal cells, which increased in number in the culture conditions used (Gomm et al., 1997a, b). Others have published work on transformed normal breast epithelial cells in culture (Yaswen et al., 1990, 1992; Stampfer and Yaswen, 1993) where resemblance to primary cancer cells may be lost.

To overcome some of these problems, we devised an immunooaffinity purification procedure using magnetic beads resulting in a very pure population of epithelial cells, as judged by PCR for luminal epithelial and myoepithelial markers. Our recent studies have demonstrated that these two populations of cells have distinct growth medium requirements in that epithelial cells require FCS, EGF and FGF, whereas myoepithelial cells are growth inhibited by FCS (Gomm et al., 1997b). We took these findings into consideration when choosing media for our cells.

In conclusion, we believe that despite the limitations in cell numbers obtained, we have established several characteristics of these cells, including viability, cytogenetics, ERα/PR status and response to oestrogen, and that this is a viable methodology for purifying small numbers of primary breast cancer cells, which will be a useful tool in the study of breast cancer biology.

REFERENCES

Cajulis RS, Frias-Hidegvi D (1993) Detection of numerical chromosomal abnormalities in malignant cells in fine needle aspirations by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes. Acta Cytol 37: 391 – 396

Clarke C, Titley J, Davies S, O’Hare MJ (1994) An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol 3: 38 – 46

Dairkee SH, Paulo EC, Traquina P, Moore DH, Ljung BM, Smith HS (1997) The human mammary epithelial cell in culture: a tool for the study of breast epithelial and myoepithelial cells. Tissue Cell 29: 2897 – 2908

Gomm JJ, Browne PJ, Coope RC, Bansal GS, Youngo C, Johnston CL, Mason R, Coombes RC (1997a) A paracrine role for myoepithelial cell-derived FGF2 in the normal mammary epithelial cell. Exp Cell Res 234: 165 – 173

Gomm JJ, Browne PJ, Coope RC, Liu QY, Buluwea L, Coombes RC (1995) Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads. Anal Biochem 226: 91 – 99

Gomm JJ, Coope RC, Browne PJ, Coombes RC (1997b) Separated human breast epithelial and myoepithelial cells have different growth factor requirements in vitro but can reconstitute normal breast lobuloalveolar structure. J Cell Physiol 171: 11 – 19

Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89: 5521 – 5525

Kamalati T, Niranjan B, Yant B, Buluwea L (1999) HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models. J Mammary Gland Biol Neoplasia 4: 69 – 77

Latza U, Niedobitek G, Schwanting R, Nekarda H, Stein H (1990) Ber-EP4: a monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 43: 213 – 219

Niranjan B, Buluwea L, Yant B, Perusinghe N, Atherton A, Phippard D, Dale T, Guenther R, Kamalati T (1995) HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 121: 2897 – 2908

Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O’Hare MJ (1999) Protemic definition of normal human luminal and myoepithelial breast cells purified from reduction mammaplasties. Proc Natl Acad Sci USA 96: 12589 – 12594

Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212 – 9217

Perou CM, Sorlie T, Eibsen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnson H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747 – 752

Persons DL, Robinson RA, Hsu PH, Seelig SA, Borell TJ, Hartmann LC, Jenkins RB (1996) Chromosome-specific aneusomy in carcinoma of the breast. Clin Cancer Res 2: 883 – 888

Petersen OW, Hoyer PE, van Deurs B (1987) Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47: 5748 – 5751

Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53: 217 – 227

Slade MJ, Coope RC, Gomm JJ, Coombes RC (1999) The human mammary gland basement membrane is integral to the polarity of luminal epithelial cells. Exp Cell Res 247: 267 – 278

Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB, Atkin SL (1998) Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer 78: 1421 – 1429

Stampfer MR, Yaswen P (1993) Culture systems for study of human mammary epithelial cell proliferation, differentiation and transformation. Cancer Surv 18: 7 – 34

Stefanini M, De Martino C, Zamboni L (1967) Fixation of ejaculated spermatozoa for electron microscopy. Nature 216: 173 – 174

Turner RC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG, Williams T (1998) Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 58: 5466 – 5472

Wijayaratne AL, McDonnell DP (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276: 35684 – 35692

Yaswen P, Smoll A, Hosoda J, Parry G, Stampfer MR (1992) Protein product of a human intronless calmodulin-like gene shows tissue-specific expression and reduced abundance in transformed cells. Cell Growth Differ 3: 335 – 345

Yaswen P, Smoll A, Pehl DM, Trask DK, Sager R, Stampfer MR (1990) Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells. Proc Natl Acad Sci USA 87: 7360 – 7364

Zhuang YH, Saaristo R, Ylikoma T (2003) An in vitro long-term culture model for normal human mammary gland: expression and regulation of steroid receptors. Cell Tissue Res 311 (2): 217 – 226